These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27109742)

  • 1. Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Wang JY; Li YJ
    Oncol Rep; 2016 Jun; 35(6):3659-68. PubMed ID: 27109742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium azulene sulfonate reverses multidrug resistance in K562/A02 cells.
    Wang Z; Zhou N; Zhao J; Zhang X
    Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):105-110. PubMed ID: 31880526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
    Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
    Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
    Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reversal of multidrug resistance by lomerizine in K562/ADM cells].
    Zhu HJ; Wu YL; Liu GQ
    Yao Xue Xue Bao; 2004 May; 39(5):333-7. PubMed ID: 15338873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
    Pan J; Miao D; Chen L
    Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Ji BS; He L; Liu GQ
    Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS; He L
    J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells.
    Mao Z; Zhou J; Luan J; Sheng W; Shen X; Dong X
    Biomed Pharmacother; 2014 Mar; 68(2):179-83. PubMed ID: 24184201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells.
    Chen JR; Jia XH; Wang H; Yi YJ; Li YJ
    Oncol Rep; 2017 May; 37(5):2735-2742. PubMed ID: 28358418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol Increases Anti-Proliferative Activity of Bestatin Through Downregulating P-Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells.
    Wang L; Wang C; Jia Y; Liu Z; Shu X; Liu K
    J Cell Biochem; 2016 May; 117(5):1233-9. PubMed ID: 26460589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
    Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
    Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reversal of mdrl gene-dependent multidrug resistance in multidrug resistance human leukemia cell line K562/ADM using short hairpin RNA expression vectors].
    Gan HZ; Zhang GZ; Lu ZX; Pu LS; Yang SJ; Gao S; Zheng DM
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):383-7. PubMed ID: 17939403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.